Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Myelodysplastic Syndromes and Immuno-Oncology

The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Geron and Syros Pharmaceuticals. This supporter has no influence over the production of the content.

View overview page
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
1:23
The current landscape of treatment for HR-MDS: an update from ASH 2023
Jacqueline Garcia • 11 Dec 2023
1:04
The challenge of treating HMA-refractory MDS patients
Samuel Urrutia • 9 Dec 2023
1:10
Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study
Uma Borate • 8 Dec 2023
2:21
MRD clearance in response to HMA + sabatolimab in HR-MDS: insights from STIMULUS-MDS1
Uwe Platzbecker • 29 Nov 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
2:21
Potential MDS targets beyond HMAs
Aditi Shastri • 8 Dec 2023
1:52
Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan • 9 Dec 2023
1:04
MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial
Marion Subklewe • 9 Dec 2023
2:14
Trial updates for luspatercept in LR-MDS: COMMANDS, MEDALIST and ELEMENTS-MDS
Amer Zeidan • 9 Dec 2023
2:21
STIMULUS-MDS1: sabatolimab + HMAs in untreated HR-MDS
Amer Zeidan • 9 Dec 2023
3:36
The genetic landscape of MDS: how this is improving & impacting the development of therapies
Jan Bewersdorf • 6 Oct 2023

The MDS Channel on VJHemOnc is supported by Bristol Myers Squibb,Geron and Syros Pharmaceuticals.

This supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The MDS Channel, please contact us.

VJHemOnc is pleased to be media partners with the MDS Foundation, visit their website to learn more.

The content of VJHemOnc is intended for healthcare professionals